ClinicalTrials.gg
CompletedNCT03465436Updated Jan 31, 2020Results posted

A Study of Lasmiditan on the Heart in Healthy Participants

A Phase 1 interventional study of Lasmiditan and Lasmiditan in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in Germany. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-31.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 6 years 4 months after the study started (first participant enrolled Sep 2011, registered Feb 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of this study was to determine how two doses of lasmiditan affected the heart in healthy participants. The study also evaluated how much lasmiditan got into the blood stream and how long it took the body to get rid of it. Information about side effects was collected. The study lasted a maximum of 46 days for each participant, not including screening.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.

Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • within 18.5 and 29.9 kilograms per meter squared (kg/m²)
  • In good physical and mental health as determined by the following:

    • Complete medical history
    • Complete physical examination
    • Vital signs including blood pressure (supine and standing), heart rate (supine and standing), respiratory rate, and temperature
    • Standard 12-lead (triplicate ECG), followed by a 24-hour Holter ECG for arrhythmia monitoring
    • Clinical laboratory tests

Exclusion criteria

Exclusion Criteria:

  • Any of the following cardiac abnormalities on safety screening :

    • interval >430 milliseconds (ms) for males, >450 ms for females
    • Unusual T wave morphology or flattened low voltage T waves
    • PR interval >240 ms or \<110 ms
    • Second-degree or third-degree atrioventricular block
    • ECG evidence of complete left or right bundle branch block
    • Intraventricular conduction delay or QRS duration >110 ms
    • Supine resting heart rate \<45 beats per minute (bpm) or >90 bpm
    • Pathological Q-waves
    • Evidence of ventricular pre-excitation
  • Participants with a history of syncope, cardiac arrest, cardiac arrhythmia or torsade de pointes, or structural heart disease
  • Participants with a family history of Long QT syndrome
  • History of allergic to lasmiditan or any component of the formulations
  • History or current evidence of abuse of any drug substance, licit or illicit, including alcohol; a positive urine screen for drugs of abuse
  • Participants with a history of postural hypotension or fainting
  • Participant is not able to understand and comply with study requirements, instructions and study restrictions
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    100 milligrams (mg) Lasmiditan

    A single, PO dose of 100 mg lasmiditan administered on Day 1 in one of four treatment periods.

    Drug: Lasmiditan

  • Experimental
    400 mg Lasmiditan

    A single, PO dose of 400 mg lasmiditan administered on Day 1 in one of four treatment periods.

    Drug: Lasmiditan

  • Placebo comparator
    Placebo

    Placebo for lasmiditan and placebo for moxifloxacin administered on Day 1 in one of four treatment periods.

    Drug: Placebo

  • Active comparator
    Moxifloxacin

    A single, PO dose of moxifloxacin administered on Day 1 in one of four treatment periods.

    Drug: Moxifloxacin

Interventions

  • 100 mg administered orally (PO)

    Also known as: LY573144

  • 400 mg administered PO

    Also known as: LY573144

  • DrugPlacebo

    Placebo administered for lasmiditan or moxifloxacin

  • 400 mg moxifloxacin administered PO

06

What researchers measure

Primary outcomes

  1. Change From Time Matched Baseline in Mean Fridericia-Corrected QT (QTcF) Values of Lasmiditan and Moxifloxacin

    The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTcF = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and R-R wave (RR), which is the interval between two R waves. PR is the interval between the P wave and the ventricular depolarization wave (QRS) complex.

    Time frame: Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose

Secondary outcomes

  1. Change From Time Matched Baseline in Mean Individually-Corrected QT (QTcI) Values of Lasmiditan and Moxifloxacin

    The corrected QT interval, individualized (QTcI) is a measurement of the electrical impulses through the largest part of the heart muscle individualized for participant pre-dose values. A negative change is a shortening of the QTc interval, a positive change is a lengthening of the QTc interval.

    Time frame: Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose

  2. Change From Baseline in Mean Cardiac Intervals: RR Interval of Lasmiditan and Moxifloxacin

    ECGs were used to calculate cardiac intervals. The RR interval is the time between two R waves.

    Time frame: Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose

  3. Change From Baseline in Mean Cardiac Intervals:QRS of Lasmiditan and Moxifloxacin

    ECGs were used to calculate cardiac intervals. The QRS interval is the time the segment of the ECG that corresponds to depolarization of the ventricles.

    Time frame: Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose

  4. Change From Baseline in Mean Heart Rate (HR) of Lasmiditan and Moxifloxacin

    Heart rate was determined during ambulatory blood pressure monitoring (ABPM).

    Time frame: Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose

  5. Number of Incidents in Electrocardiogram (ECG) Abnormalities in QTcF Interval Greater Than 450 Milliseconds

    ECGs were assessed for morphology abnormalities or changes in QTcf interval greater than 450 milliseconds by a board-certified cardiologist

    Time frame: Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose

  6. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lasmiditan

    Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lasmiditan.

    Time frame: Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose

  7. Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC-t) of Lasmiditan

    Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC-t) of Lasmiditan.

    Time frame: Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose

07

Results

Posted Jan 31, 2020

Participant flow

Period 1
Participant flow — Period 1
MilestoneSequence 1 ABDCSequence 2 BCADSequence 3 CDBASequence 4 DACB
Started14141414
Received at least 1 dose of study drug14141414
Completed14141314
Not completed0010
Withdrew: Protocol violation0010
Period 2
Participant flow — Period 2
MilestoneSequence 1 ABDCSequence 2 BCADSequence 3 CDBASequence 4 DACB
Started14141314
Received at least 1 dose of study drug14131314
Completed14131314
Not completed0100
Withdrew: Protocol violation0100
Period 3
Participant flow — Period 3
MilestoneSequence 1 ABDCSequence 2 BCADSequence 3 CDBASequence 4 DACB
Started14131314
Received at least one dose of study drug13121314
Completed13121314
Not completed1100
Withdrew: Protocol violation1100
Period 4
Participant flow — Period 4
MilestoneSequence 1 ABDCSequence 2 BCADSequence 3 CDBASequence 4 DACB
Started13121314
Received at least 1 dose of study drug13121314
Completed13121214
Not completed0010
Withdrew: Protocol violation0010

Outcome measures

PrimaryChange From Time Matched Baseline in Mean Fridericia-Corrected QT (QTcF) Values of Lasmiditan and Moxifloxacin

The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTcF = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and R-R wave (RR), which is the interval between two R waves. PR is the interval between the P wave and the ventricular depolarization wave (QRS) complex.

Time frame:
Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose
Reported as:
Mean · milliseconds
Change From Time Matched Baseline in Mean Fridericia-Corrected QT (QTcF) Values of Lasmiditan and Moxifloxacin
milliseconds100 mg Lasmiditan400 mg LasmiditanPlaceboMoxifloxacin
30 minutes postdose-8.90 ± 7.20-9.27 ± 6.29-5.49 ± 5.521.90 ± 8.69
1 hour postdose-7.42 ± 5.83-4.58 ± 8.13-3.94 ± 5.158.36 ± 6.51
1.5 hours postdose-7.63 ± 5.98-3.07 ± 7.91-3.68 ± 4.667.63 ± 6.32
2 hours postdose-6.96 ± 7.08-1.12 ± 8.10-3.83 ± 5.288.16 ± 7.21
2.5 hours postdose-5.26 ± 7.360.15 ± 8.67-2.89 ± 4.998.12 ± 7.15
3 hours postdose-2.81 ± 6.952.06 ± 8.18-2.04 ± 5.7110.01 ± 6.42
3.5 hours postdose-2.39 ± 7.633.58 ± 6.88-1.85 ± 4.5910.37 ± 7.09
4 hours postdose-2.12 ± 6.894.77 ± 7.49-2.34 ± 5.659.39 ± 5.85
6 hours postdose-4.33 ± 7.32-0.18 ± 7.38-3.39 ± 6.594.91 ± 7.05
8 hours postdose-6.74 ± 7.16-1.84 ± 7.82-3.99 ± 7.113.90 ± 7.13
12 hours postdose-3.73 ± 5.72-0.41 ± 6.99-1.79 ± 5.914.63 ± 7.12
24 hours postdose0.74 ± 7.510.38 ± 7.060.45 ± 6.186.61 ± 7.91
Statistical analysis
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -3.50 · 90% CI -5.41 to -1.59
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -3.54 · 90% CI -5.18 to -1.89
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -4.10 · 90% CI -5.77 to -2.43
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -3.21 · 90% CI -5.14 to -1.28
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -2.46 · 90% CI -4.41 to -0.51
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -0.91 · 90% CI -2.84 to 1.03
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -0.62 · 90% CI -2.53 to 1.29
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 0.07 · 90% CI -1.84 to 1.99
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -1.06 · 90% CI -3.22 to 1.10
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -2.73 · 90% CI -4.88 to -0.57
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -2.05 · 90% CI -3.77 to -0.32
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 0.21 · 90% CI -1.90 to 2.33
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -3.83 · 90% CI -5.56 to -2.11
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -0.75 · 90% CI -2.75 to 1.25
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 0.45 · 90% CI -1.49 to 2.38
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 2.58 · 90% CI 0.58 to 4.58
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 2.85 · 90% CI 0.73 to 4.98
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 3.94 · 90% CI 1.85 to 6.03
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 5.28 · 90% CI 3.61 to 6.95
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 6.94 · 90% CI 4.99 to 8.89
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 3.13 · 90% CI 0.93 to 5.34
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 2.09 · 90% CI -0.23 to 4.40
  • 400 mg Lasmiditan · Mixed Models Analysis · Ls mean: 1.37 · 90% CI -0.57 to 3.30
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -0.29 · 90% CI -2.21 to 1.63
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 7.32 · 90% CI 5.03 to 9.60
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 12.28 · 90% CI 10.47 to 14.10
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 11.27 · 90% CI 9.54 to 13.00
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 11.92 · 90% CI 9.97 to 13.87
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 10.98 · 90% CI 9.17 to 12.79
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 11.99 · 90% CI 10.10 to 13.87
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 12.19 · 90% CI 10.32 to 14.05
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 11.68 · 90% CI 9.83 to 13.52
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 8.24 · 90% CI 6.10 to 10.39
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 7.87 · 90% CI 5.66 to 10.07
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 6.35 · 90% CI 4.32 to 8.38
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 6.13 · 90% CI 3.88 to 8.38
SecondaryChange From Time Matched Baseline in Mean Individually-Corrected QT (QTcI) Values of Lasmiditan and Moxifloxacin

The corrected QT interval, individualized (QTcI) is a measurement of the electrical impulses through the largest part of the heart muscle individualized for participant pre-dose values. A negative change is a shortening of the QTc interval, a positive change is a lengthening of the QTc interval.

Time frame:
Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose
Reported as:
Mean · milliseconds
Change From Time Matched Baseline in Mean Individually-Corrected QT (QTcI) Values of Lasmiditan and Moxifloxacin
milliseconds100 mg Lasmiditan400 mg LasmiditanPlaceboMoxifloxacin
30 minutes postdose-9.92 ± 7.62-10.56 ± 8.00-5.27 ± 6.042.24 ± 8.88
1 hour postdose-9.50 ± 7.74-6.90 ± 8.98-3.35 ± 5.528.96 ± 7.14
1.5 hours postdose-9.39 ± 6.93-4.73 ± 8.29-2.81 ± 5.588.61 ± 6.42
2 hours postdose-8.74 ± 8.34-2.65 ± 8.56-3.49 ± 5.828.29 ± 7.03
2.5 hours postdose-7.90 ± 9.42-1.80 ± 8.84-2.44 ± 5.618.40 ± 7.53
3 hours postdose-5.08 ± 8.29-0.13 ± 8.63-1.70 ± 6.1011.01 ± 6.89
3.5 hours postdose-3.86 ± 8.721.90 ± 7.48-1.67 ± 5.0111.43 ± 7.38
4 hours postdose-3.25 ± 8.073.27 ± 8.44-1.19 ± 6.3710.28 ± 6.50
6 hours postdose-4.84 ± 7.00-1.27 ± 6.65-3.13 ± 6.614.85 ± 7.37
8 hours postdose-7.10 ± 7.76-3.08 ± 8.23-3.89 ± 6.774.04 ± 7.01
12 hours postdose-4.08 ± 5.88-0.64 ± 6.86-1.65 ± 6.094.87 ± 7.14
24 hours postdose1.60 ± 6.840.45 ± 6.850.81 ± 6.226.74 ± 8.14
Statistical analysis
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -4.49 · 90% CI -6.47 to -2.52
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -5.30 · 90% CI -7.18 to -3.42
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -5.70 · 90% CI -7.57 to -3.82
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -4.47 · 90% CI -6.64 to -2.30
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -4.53 · 90% CI -6.87 to -2.19
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -2.74 · 90% CI -4.90 to -0.59
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -1.74 · 90% CI -3.86 to 0.39
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -1.66 · 90% CI -3.77 to 0.44
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -1.11 · 90% CI -3.17 to 0.94
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -2.47 · 90% CI -4.58 to -0.35
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -2.15 · 90% CI -3.87 to -0.43
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 0.79 · 90% CI -1.14 to 2.72
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -4.64 · 90% CI -6.57 to -2.71
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -2.49 · 90% CI -4.59 to -0.39
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -0.96 · 90% CI -3.02 to 1.09
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 1.64 · 90% CI -0.46 to 3.73
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 1.61 · 90% CI -0.59 to 3.81
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 2.41 · 90% CI 0.25 to 4.57
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 4.30 · 90% CI 2.48 to 6.12
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 5.15 · 90% CI 3.02 to 7.27
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 2.77 · 90% CI 0.75 to 4.79
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 1.75 · 90% CI -0.55 to 4.05
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 1.75 · 90% CI -0.19 to 3.69
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -0.48 · 90% CI -2.44 to 1.48
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 7.07 · 90% CI 4.72 to 9.41
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 11.81 · 90% CI 9.94 to 13.69
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 10.95 · 90% CI 9.16 to 12.74
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 11.50 · 90% CI 9.5 to 13.43
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 10.81 · 90% CI 8.9 to 12.71
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 12.35 · 90% CI 10.42 to 14.28
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 12.65 · 90% CI 10.76 to 14.54
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 11.17 · 90% CI 9.23 to 13.10
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 8.12 · 90% CI 6.02 to 10.22
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 8.10 · 90% CI 6.01 to 10.19
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 6.26 · 90% CI 4.23 to 8.28
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 5.74 · 90% CI 3.47 to 8.01
SecondaryChange From Baseline in Mean Cardiac Intervals: RR Interval of Lasmiditan and Moxifloxacin

ECGs were used to calculate cardiac intervals. The RR interval is the time between two R waves.

Time frame:
Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose
Reported as:
Mean · milliseconds
Change From Baseline in Mean Cardiac Intervals: RR Interval of Lasmiditan and Moxifloxacin
milliseconds100 mg Lasmiditan400 mg LasmiditanPlaceboMoxifloxacin
30 minutes postdose74.40 ± 76.2698.52 ± 72.9942.13 ± 56.0018.66 ± 61.84
1 hour postdose149.22 ± 77.73153.15 ± 65.1349.87 ± 62.409.63 ± 63.32
1.5 hours postdose143.29 ± 80.63130.79 ± 55.9136.84 ± 66.5213.44 ± 61.66
2 hours postdose118.39 ± 60.84128.10 ± 48.5044.69 ± 53.7026.01 ± 54.44
2.5 hours postdose117.90 ± 73.85132.86 ± 54.3529.28 ± 51.3926.90 ± 68.18
3 hours postdose105.56 ± 63.82119.52 ± 60.6630.84 ± 57.2824.87 ± 66.41
3.5 hours postdose89.85 ± 56.54101.86 ± 59.0436.77 ± 50.3419.01 ± 65.56
4 hours postdose72.22 ± 57.1983.00 ± 56.8430.32 ± 51.1113.64 ± 68.55
6 hours postdose-26.01 ± 69.03-3.07 ± 63.34-88.95 ± 60.15-84.12 ± 63.34
8 hours postdose5.63 ± 73.5829.01 ± 66.89-50.89 ± 75.72-49.70 ± 52.21
12 hours postdose-26.70 ± 77.945.19 ± 73.16-61.53 ± 76.51-74.80 ± 70.71
24 hours postdose-16.37 ± 68.00-5.64 ± 63.34-11.66 ± 60.48-13.02 ± 52.97
Statistical analysis
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 32.89 · 90% CI 11.50 to 54.28
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 100.15 · 90% CI 77.81 to 122.50
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 107.11 · 90% CI 83.31 to 130.91
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 74.48 · 90% CI 56.32 to 92.63
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 89.19 · 90% CI 68.77 to 109.61
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 74.98 · 90% CI 55.41 to 94.55
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 52.83 · 90% CI 36.03 to 69.63
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 42.10 · 90% CI 24.86 to 59.35
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 62.61 · 90% CI 42.39 to 82.83
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 56.05 · 90% CI 32.49 to 79.61
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 35.71 · 90% CI 11.79 to 59.63
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -4.59 · 90% CI -24.66 to 15.47
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 56.53 · 90% CI 36.72 to 76.35
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 103.30 · 90% CI 83.88 to 122.72
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 94.21 · 90% CI 75.15 to 113.26
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 83.49 · 90% CI 67.98 to 99.00
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 103.64 · 90% CI 87.28 to 120.00
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 89.26 · 90% CI 71.24 to 107.29
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 65.29 · 90% CI 48.28 to 82.30
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 52.85 · 90% CI 36.10 to 69.60
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 86.09 · 90% CI 66.36 to 105.82
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 80.12 · 90% CI 58.32 to 101.91
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 67.58 · 90% CI 44.64 to 90.51
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 7.77 · 90% CI -10.01 to 25.55
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: -22.02 · 90% CI -38.44 to -5.60
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: -38.87 · 90% CI -57.15 to -20.60
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: -22.13 · 90% CI -39.35 to -4.91
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: -17.35 · 90% CI -32.15 to -2.56
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: -1.03 · 90% CI -18.17 to 16.12
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: -4.77 · 90% CI -21.81 to 12.27
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: -16.56 · 90% CI -33.36 to 0.24
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: -15.29 · 90% CI -32.94 to 2.37
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 6.13 · 90% CI -10.86 to 23.11
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 2.27 · 90% CI -15.25 to 19.80
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: -11.95 · 90% CI -33.46 to 9.56
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: -0.31 · 90% CI -17.32 to 16.69
SecondaryChange From Baseline in Mean Cardiac Intervals:QRS of Lasmiditan and Moxifloxacin

ECGs were used to calculate cardiac intervals. The QRS interval is the time the segment of the ECG that corresponds to depolarization of the ventricles.

Time frame:
Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose
Reported as:
Mean · milliseconds
Change From Baseline in Mean Cardiac Intervals:QRS of Lasmiditan and Moxifloxacin
milliseconds100 mg Lasmiditan400 mg LasmiditanPlaceboMoxifloxacin
30 minutes postdose0.11 ± 1.12-0.10 ± 1.230.09 ± 1.28-0.00 ± 0.97
1 hours postdose-0.24 ± 1.210.45 ± 1.35-0.02 ± 1.20-0.12 ± 1.07
1.5 hours postdose-0.48 ± 1.130.19 ± 1.24-0.37 ± 1.06-0.12 ± 1.09
2 hours postdose-0.73 ± 1.120.10 ± 1.08-0.30 ± 1.22-0.29 ± 1.14
2.5 hours postdose-0.75 ± 1.410.30 ± 1.22-0.21 ± 1.08-0.20 ± 1.11
3 hours postdose-0.63 ± 1.210.08 ± 1.19-0.26 ± 1.19-0.35 ± 0.93
3.5 hours postdose-0.58 ± 1.000.15 ± 1.15-0.17 ± 0.98-0.57 ± 1.34
4 hours postdose-0.54 ± 1.030.29 ± 1.17-0.20 ± 0.95-0.58 ± 1.25
6 hours postdose0.20 ± 1.430.64 ± 1.500.73 ± 1.340.13 ± 1.39
8 hours postdose-0.41 ± 1.36-0.39 ± 1.43-0.28 ± 1.38-0.67 ± 1.34
12 hours postdose0.34 ± 1.460.24 ± 1.670.63 ± 1.050.32 ± 1.52
24 hours postdose0.33 ± 1.22-0.07 ± 1.22-0.10 ± 1.320.09 ± 1.28
Statistical analysis
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 0.02 · 90% CI -0.37 to 0.41
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -0.23 · 90% CI -0.61 to 0.15
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -0.12 · 90% CI -0.47 to 0.23
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -0.44 · 90% CI -0.81 to -0.07
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -0.55 · 90% CI -0.95 to -0.15
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -0.38 · 90% CI -0.77 to 0.00
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -0.41 · 90% CI -0.72 to -0.10
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -0.35 · 90% CI -0.66 to -0.04
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -0.54 · 90% CI -0.98 to -0.09
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -0.14 · 90% CI -0.58 to 0.31
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -0.29 · 90% CI -0.70 to 0.12
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 0.43 · 90% CI 0.01 to 0.84
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -0.19 · 90% CI -0.59 to 0.21
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 0.48 · 90% CI 0.06 to 0.89
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 0.56 · 90% CI 0.19 to 0.93
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 0.40 · 90% CI 0.02 to 0.77
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 0.51 · 90% CI 0.13 to 0.88
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 0.33 · 90% CI -0.05 to 0.71
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 0.32 · 90% CI -0.02 to 0.67
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 0.50 · 90% CI 0.16 to 0.84
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -0.10 · 90% CI -0.56 to 0.36
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -0.11 · 90% CI -0.56 to 0.33
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -0.39 · 90% CI -0.84 to 0.06
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 0.04 · 90% CI -0.37 to 0.45
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: -0.09 · 90% CI -0.45 to 0.28
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: -0.10 · 90% CI -0.46 to 0.27
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 0.25 · 90% CI -0.10 to 0.60
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 0.01 · 90% CI -0.38 to 0.40
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 0.02 · 90% CI -0.34 to 0.37
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: -0.09 · 90% CI -0.44 to 0.25
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: -0.39 · 90% CI -0.76 to -0.03
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: -0.38 · 90% CI -0.73 to -0.03
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: -0.60 · 90% CI -1.03 to -0.17
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: -0.39 · 90% CI -0.82 to 0.04
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: -0.31 · 90% CI -0.70 to 0.09
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 0.19 · 90% CI -0.23 to 0.61
SecondaryChange From Baseline in Mean Heart Rate (HR) of Lasmiditan and Moxifloxacin

Heart rate was determined during ambulatory blood pressure monitoring (ABPM).

Time frame:
Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose
Reported as:
Mean · beats per minute
Change From Baseline in Mean Heart Rate (HR) of Lasmiditan and Moxifloxacin
beats per minute100 mg Lasmiditan400 mg LasmiditanPlaceboMoxifloxacin
30 minutes postdose-3.90 ± 5.05-5.51 ± 3.74-2.41 ± 3.22-1.02 ± 3.75
1 hour postdose-7.82 ± 3.95-8.40 ± 3.21-2.77 ± 3.55-0.42 ± 4.05
1.5 hours postdose-7.55 ± 4.16-7.41 ± 3.14-2.01 ± 3.53-0.67 ± 3.73
2 hours postdose-6.62 ± 3.22-7.30 ± 2.93-2.65 ± 3.17-1.52 ± 3.19
2.5 hours postdose-6.49 ± 4.07-7.59 ± 3.27-1.75 ± 2.97-1.48 ± 4.07
3 hours postdose-5.96 ± 3.32-6.82 ± 3.53-1.83 ± 3.35-1.26 ± 3.95
3.5 hours postdose-5.26 ± 3.02-6.02 ± 3.50-2.32 ± 3.06-0.91 ± 4.23
4 hours postdose-4.22 ± 3.06-5.02 ± 3.42-1.82 ± 3.19-0.55 ± 4.37
6 hours postdose1.65 ± 4.52-0.10 ± 3.776.29 ± 5.185.84 ± 4.84
8 hours postdose-0.43 ± 4.73-1.96 ± 3.933.42 ± 5.053.10 ± 3.42
12 hours postdose1.58 ± 5.31-0.50 ± 4.664.17 ± 5.464.95 ± 5.12
24 hours postdose1.01 ± 4.450.42 ± 4.090.89 ± 3.960.81 ± 3.60
Statistical analysis
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -1.53 · 90% CI -2.90 to -0.16
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -5.09 · 90% CI -6.29 to -3.88
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -5.57 · 90% CI -6.81 to -4.32
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -4.01 · 90% CI -5.00 to -3.01
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -4.78 · 90% CI -5.91 to -3.65
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -4.14 · 90% CI -5.20 to -3.08
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -2.94 · 90% CI -3.87 to -2.01
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -2.42 · 90% CI -3.42 to -1.42
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -4.61 · 90% CI -6.17 to -3.06
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -3.82 · 90% CI -5.38 to -2.26
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -2.65 · 90% CI -4.33 to -0.97
  • 100 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: 0.12 · 90% CI -1.22 to 1.46
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -3.09 · 90% CI -4.16 to -2.02
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -5.61 · 90% CI -6.65 to -4.58
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -5.39 · 90% CI -6.42 to -4.35
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -4.64 · 90% CI -5.55 to -3.72
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -5.82 · 90% CI -6.77 to -4.87
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -4.99 · 90% CI -6.03 to -3.96
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -3.69 · 90% CI -4.68 to -2.71
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -3.19 · 90% CI -4.21 to -2.17
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -6.29 · 90% CI -7.83 to -4.95
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -5.37 · 90% CI -6.73 to -4.02
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -4.71 · 90% CI -6.25 to -3.17
  • 400 mg Lasmiditan vs Placebo · Mixed Models Analysis · Ls mean: -0.55 · 90% CI -1.74 to 0.63
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 1.32 · 90% CI 0.32 to 2.33
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 2.29 · 90% CI 1.19 to 3.40
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 1.30 · 90% CI 0.31 to 2.28
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 1.07 · 90% CI 0.17 to 1.97
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 0.21 · 90% CI -0.81 to 1.23
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 0.53 · 90% CI -0.50 to 1.56
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 1.36 · 90% CI 0.29 to 2.44
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 1.21 · 90% CI 0.09 to 2.34
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: -0.49 · 90% CI -1.97 to 0.99
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: -0.36 · 90% CI -1.54 to 0.83
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: 0.73 · 90% CI -0.87 to 2.34
  • Placebo vs Moxifloxacin · Mixed Models Analysis · Ls mean: -0.12 · 90% CI -1.29 to 1.04
SecondaryNumber of Incidents in Electrocardiogram (ECG) Abnormalities in QTcF Interval Greater Than 450 Milliseconds

ECGs were assessed for morphology abnormalities or changes in QTcf interval greater than 450 milliseconds by a board-certified cardiologist

Time frame:
Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose
Reported as:
Number · Incidents
Number of Incidents in Electrocardiogram (ECG) Abnormalities in QTcF Interval Greater Than 450 Milliseconds
Incidents100 mg Lasmiditan400 mg LasmiditanPlaceboMoxifloxacin
Predose0000
30 minutes postdose0001
1 hour postdose2002
1.5 hours postdose0102
2 hours postdose1103
2.5 hours postdose1102
3 hours postdose1102
3.5 hours postdose1203
4 hours postdose1103
6 hours postdose0000
8 hours postdose0100
12 hours postdose0000
24 hours postdose0000
SecondaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Lasmiditan

Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lasmiditan.

Time frame:
Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose
Reported as:
Mean · nanogram per milliliter
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lasmiditan
nanogram per milliliter100 mg Lasmiditan400 mg Lasmiditan
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lasmiditan104.55 ± 41.452526.15 ± 240.997
SecondaryPharmacokinetics (PK): Area Under the Concentration Time Curve (AUC-t) of Lasmiditan

Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC-t) of Lasmiditan.

Time frame:
Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose
Reported as:
Geometric mean · hours*nanogram per milliliter
Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC-t) of Lasmiditan
hours*nanogram per milliliter100 mg Lasmiditan400 mg Lasmiditan
Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC-t) of Lasmiditan684.66 ± 278.2583189.08 ± 1152.338

Adverse events

Collected over 75 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
100 mg Lasmiditan0/52 (0%)0/52 (0%)21/52 (40.4%)
400 mg Lasmiditan0/55 (0%)0/55 (0%)33/55 (60%)
Placebo0/54 (0%)0/54 (0%)7/54 (13%)
Moxifloxacin0/52 (0%)1/52 (1.9%)9/52 (17.3%)
Most frequent serious events
Most frequent serious events
Event100 mg Lasmiditan400 mg LasmiditanPlaceboMoxifloxacin
Pilonidal cystInfections and infestations0/520/550/541/52
Most frequent other events
Most frequent other events
Event100 mg Lasmiditan400 mg LasmiditanPlaceboMoxifloxacin
DizzinessNervous system disorders14/5223/553/540/52
SomnolenceNervous system disorders13/5222/553/544/52
ParaesthesiaNervous system disorders5/528/550/540/52
NauseaGastrointestinal disorders4/522/550/544/52
AstheniaGeneral disorders0/524/550/540/52
NasopharyngitisInfections and infestations1/522/552/543/52
DiscomfortGeneral disorders0/523/550/540/52
Muscular weaknessMusculoskeletal and connective tissue disorders0/523/550/540/52
DysarthriaNervous system disorders0/523/550/540/52
Restless legs syndromeNervous system disorders0/523/550/540/52

Baseline characteristics

All randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Sequence 1 ABDCSequence 2 BCADSequence 3 CDBASequence 4 DACBTotal
Mean40.6 ± 12.338.4 ± 11.737.5 ± 10.840.7 ± 9.139.3 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)Sequence 1 ABDCSequence 2 BCADSequence 3 CDBASequence 4 DACBTotal
Female975627
Male579829
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sequence 1 ABDCSequence 2 BCADSequence 3 CDBASequence 4 DACBTotal
Hispanic or Latino00000
Not Hispanic or Latino1414141456
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sequence 1 ABDCSequence 2 BCADSequence 3 CDBASequence 4 DACBTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American01001
White1313141353
More than one race00000
Unknown or Not Reported10012
Region of Enrollment
Region of Enrollment(Participants)Sequence 1 ABDCSequence 2 BCADSequence 3 CDBASequence 4 DACBTotal
Germany1414141456
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Berlin, 14050, Germany
09

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2011 to primary completion in Dec 2011, 3 months.

Results were first posted in Jan 2020, 8 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2018
First posted
Mar 14, 2018
StartActual
Sep 16, 2011
Primary completionActual
Dec 20, 2011
CompletionActual
Dec 20, 2011
Results first posted
Jan 31, 2020
Last update
Jan 31, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03465436
Collaborators
CoLucid Pharmaceuticals
Responsible party
Sponsor
First posted
Mar 14, 2018
Start date
Sep 16, 2011
Primary completion
Dec 20, 2011
Completion
Dec 20, 2011
Results posted
Jan 31, 2020
Last update
Jan 31, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lasmiditan

Start the discussion